![\"Nancy](\"https:\/\/www.healio.com\/~\/media\/images\/news\/print\/healio-gastroenterology\/2019\/07_july\/reau_nancys.jpg?w=80\")
\n<\/div>\nHepatitis C virus elimination is a critical public health objective. Untreated chronic infection leads to end-stage liver disease, hepatocellular carcinoma and substantial liver-related mortality, all of which are preventable given the availability of curative, well-tolerated, oral direct-acting antivirals that achieve sustained virologic response in over 95% of patients.<\/p>\n
Untreated individuals are also at high risk of transmitting the infection; this is especially true among those actively injecting drugs. Beyond averting billions of dollars in long-term downstream healthcare costs, universal elimination acts as a powerful form of treatment-as-prevention to halt community transmission.<\/p>\n
Despite possessing the diagnostic and therapeutic tools necessary to meet WHO and CDC elimination targets, the United States struggles to achieve these goals due to severe structural and policy fragmentation. Persistent barriers include steep dropoffs along the diagnostic-to-treatment care cascade; restrictive state Medicaid prior authorization policies, such as sobriety mandates or specialist-only prescribing rules; and high drug-acquisition costs.<\/p>\n
Furthermore, the highest incidence and ongoing transmission remain heavily concentrated within marginalized, structurally vulnerable populations \u2014 predominantly people who inject drugs, individuals experiencing unsheltered homelessness and incarcerated persons \u2014 who face pervasive medical stigma, criminalization and systemic disconnects from traditional healthcare systems.<\/p>\n
Without a federally coordinated, low-barrier elimination initiative that pairs subscription-based drug procurement models with decentralized, point-of-care harm reduction delivery, the gap between clinical curability and population-level eradication will persist.<\/p>\n
Although treating 15 individuals may seem like a resource heavy intervention for a few, the number of secondary HCV infections generated by a single index person who injects drugs is significant in hyperconnected social transmission networks. Transmission is profoundly nonlinear. Outbreak investigations and social network tracing studies have documented single index individuals initiating transmission chains that infect 20 to 30-plus individuals within a 6- to 12-month window.<\/p>\n
This study also included multiple core facilitators: Tailored low-barrier interventions (eg, dispensing 1-week supplies, field-delivered reflex testing, text reminders and pillboxes) and trusting, non-stigmatizing patient-provider relationships directly overcame traditional structural obstacles.<\/p>\n
In addition to HCV cure, participants reported downstream psychosocial transformation, including a heightened sense of agency, renewed commitment to broader personal health and safer use practices, and spontaneous peer-to-peer outreach.<\/p>\n
The study also highlighted that clinician confidence scores at baseline did not correlate with actual completion or cure rates, underscoring that subjective provider hesitation often underestimates patient readiness when structural support is in place.<\/p>\n
Without innovation, the U.S. will remain woefully off target for HCV elimination. This is especially relevant as the CARES Act progresses through the approval process, giving us resources to help achieve the WHO target.<\/p>\n
\nReference:<\/b>\n<\/p>\n